CGTLive’s Weekly Rewind – July 7, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Hope Remains for CAR-T Approaches in Ovarian Cancer

Mary “Nora” Disis, MD, a professor of medicine at the University of Washington Fred Hutchinson Cancer Center, discussed past and current clinical trials for investigational CAR-T therapies in ovarian cancer.

2. Krystof Bankiewicz, MD, PhD, on GDNF Gene Therapy for Parkinson’s and AADC Deficiency

The professor at Ohio State University and University of California – San Francisco discussed investigations with different delivery methods of GDNF gene therapy.

3. Duchenne Muscular Dystrophy Cell Therapy CAP-1002 Demonstrates Improvements in LVEF

In terms of safety, Capricor Therapeutics’ CAP-1002 was reported to be well-tolerated.

4. Brian Culley, MS, on Sharing Knowledge From the Development of Spinal Cord Injury Cell Therapy

The chief executive officer of Lineage Cell Therapeutics discussed findings related to its cell therapy OPC1 that the company presented at the first Annual SCI Investor Symposium.

5. Insulin-Producing Islet Cell Therapy VX-880 Meets Primary Efficacy End Point in Patients With Type 1 Diabetes

The 2 patients were among 6 who have received treatment in Vertex’s trial so far and were the only 2 evaluable for the primary efficacy end point.